Drugs that contain Inclisiran Sodium
1. List of Leqvio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(10 months ago) | |
| US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(9 months ago) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(13 days from now) | |
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(8 months from now) | |
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(10 months from now) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 30 days from now) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 30 days from now) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 30 days from now) | |
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(4 years from now) | |
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(6 months ago) | |
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(8 months from now) | |
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(4 years from now) | |
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
NCE-1 date: December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic